Review: Daptomycin for the treatment of gram-positive infections in neutropenic cancer patients.
Rolston
Kenneth V I
KV
Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. krolston@mdanderson.org
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017576:Daptomycin / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D014640:Vancomycin / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin; D017576:Daptomycin